Biotech RadarJobs updated

COMPANY

Travere Therapeutics

HQ: San Diego, CA source · travere.com ↗ · West Coast

FDA-approved therapeutic company Clinical Phase 3

44 open jobs · last seen Oct 23, 2026 · 18 sources

Keywords: metabolic renal metabolic diseases disease of metabolism Homocystinuria Focal Segmental Glomerulosclerosis Immunoglobulin A Nephropathy Homocystinuria Due to CBS Deficiency Proteinuria Immunoglobulin A (IgA) Nephropathy Kidney Transplant Minimal Change Disease IgA Vasculitis Alport Syndrome Cerebrotendinous Xanthomatosis Pantothenate Kinase-Associated Neurodegeneration Pegtibatinase Sparsentan RE-021 (Sparsentan) Fosmetpantotenate

Profile checked Oct 10, 2026

Since the raise (Nov 12, 2024): 44 of 44 open jobs were first seen after it.

44Open jobs$143.8MRaised (2 yrs)14Trials (company is sponsor)2FDA records (2 yrs)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Executive Director, Clinical Development2 locations (listed on the posting)Oct 20, 2026Oct 21, 2026
Executive Director, Health Economics & Outcomes Research (HEOR)2 locations (listed on the posting)Oct 20, 2026Oct 21, 2026
Executive Director, Field Operations Strategy & Excellence2 locations (listed on the posting)Oct 20, 2026Oct 21, 2026
Director, Enterprise Infrastructure Engineering & Operations2 locations (listed on the posting)Oct 16, 2026Oct 5, 2026
Senior Director, Marketing & Launch Lead, Pegtibatinase2 locations (listed on the posting)Oct 16, 2026Oct 5, 2026

See all 44 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (44 open jobs at last check). source ↗
  2. Debt Debt: $475M (not counted as a raise), announced May 11, 2026. Source: SEC filing. source ↗
  3. FDA FDA New indication / efficacy supplement: FILSPARI (sparsentan) — NDA216403/6, Apr 13, 2026. Applicant at approval: Travere Therapeutics, Inc. source ↗
  4. Trial start Phase 4: Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis source ↗
  5. FDA FDA New indication / efficacy supplement: FILSPARI (sparsentan) — NDA216403/5, Aug 27, 2025. Applicant at approval: Travere Therapeutics, Inc. source ↗
  6. Raise Follow-on offering: $143.8M (total, as published), announced Nov 12, 2024. Source: company release on GlobeNewswire. source ↗
  7. Trial start Phase 3: A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) source ↗
  8. Trial start Phase 3: Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment source ↗
  9. Trial start Phase 2: A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN source ↗
  10. Trial start —: Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) source ↗
  11. Trial start Phase 2: Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases source ↗
  12. Trial start Phase 1: Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension source ↗
  13. Trial start Phase 1/Phase 2: Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study) source ↗
  14. Trial start Phase 3: A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy source ↗
  15. Trial start Phase 3: Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) source ↗
  16. Trial start Phase 3: Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants source ↗
  17. Trial start —: Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA) source ↗
  18. Trial start —: Cerebrotendinous Xanthomatosis (CTX) Prevalence Study source ↗
  19. Trial start Phase 2: Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 44

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Executive Director, Clinical Development2 locations (listed on the posting)Oct 20, 2026Oct 21, 2026Not stated
Executive Director, Health Economics & Outcomes Research (HEOR)2 locations (listed on the posting)Oct 20, 2026Oct 21, 2026Not stated
Executive Director, Field Operations Strategy & Excellence2 locations (listed on the posting)Oct 20, 2026Oct 21, 2026Not stated
Director, Enterprise Infrastructure Engineering & Operations2 locations (listed on the posting)Oct 16, 2026Oct 5, 2026Senior
Senior Director, Marketing & Launch Lead, Pegtibatinase2 locations (listed on the posting)Oct 16, 2026Oct 5, 2026Senior
Associate Director, Search and Evaluation2 locations (listed on the posting)Oct 15, 2026Oct 5, 2026Senior
Executive Director, Translational Medicine & Pediatric Planning2 locations (listed on the posting)Oct 15, 2026Oct 16, 2026Not stated
Senior Manager, Statistical Programming2 locations (listed on the posting)Oct 15, 2026Oct 16, 2026Not stated
Associate Director, Data Management2 locations (listed on the posting)Oct 15, 2026Oct 16, 2026Not stated
Senior Manager, Drug Safety & Pharmacovigilance2 locations (listed on the posting)Oct 15, 2026Oct 16, 2026Not stated
Senior Thought Leader Liaison (Southwest)4 locations, including Remote, CaliforniaOct 13, 2026Oct 13, 2026Senior
Director, Medical Science Liaison - MetabolicUSA- RemoteOct 12, 2026Oct 12, 2026Senior
Associate Director, Clinical Scientist2 locations (listed on the posting)Oct 12, 2026Oct 12, 2026Senior
Associate Director, Quality Assurance - Technical2 locations (listed on the posting)Oct 12, 2026Oct 13, 2026Senior
Director, Scientific Communications - Medical Content (Sparsentan)2 locations (listed on the posting)Oct 8, 2026Oct 8, 2026Senior
Director, Specialty Pharmacy, Trade, & Distribution2 locations (listed on the posting)Oct 7, 2026Oct 8, 2026Senior
Director, Clinical Science2 locations (listed on the posting)Oct 2, 2026Oct 5, 2026Senior
Director, Biologics CMC Technical Writing2 locations (listed on the posting)Sep 30, 2026Oct 5, 2026Senior
Associate Director, Commercial Manufacturing & Packaging2 locations (listed on the posting)Sep 29, 2026Oct 5, 2026Senior
Associate Director, Technical Operations2 locations (listed on the posting)Sep 29, 2026Oct 5, 2026Senior
Associate Director, Customer Engagement Platforms & Data2 locations (listed on the posting)Sep 25, 2026Oct 5, 2026Senior
Vice President, US Patient Access2 locations (listed on the posting)Sep 25, 2026Oct 5, 2026Executive
Senior Director, Enterprise Technology & Solutions2 locations (listed on the posting)Sep 24, 2026Oct 5, 2026Senior
Thought Leader Liaison (South Central)3 locations, including Remote, TexasSep 23, 2026Oct 5, 2026Senior
Access & Reimbursement Manager (Southern California)California - RemoteSep 23, 2026Oct 5, 2026Mid
Director, Product & Pipeline Communications2 locations (listed on the posting)Sep 23, 2026Oct 5, 2026Senior
Associate Director, Regulatory Labeling Strategy2 locations (listed on the posting)Sep 23, 2026Oct 5, 2026Senior
Executive Director, Corporate Development2 locations (listed on the posting)Sep 23, 2026Oct 5, 2026Executive
Director, New Product Planning & Commercial DiligenceSan DiegoSep 23, 2026Oct 5, 2026Senior
Senior Quality Assurance Associate - GMP/GDP Auditing2 locations (listed on the posting)Sep 23, 2026Oct 5, 2026Senior
Associate Director, Clinical Pharmacology2 locations (listed on the posting)Sep 23, 2026Oct 7, 2026Senior
Principal Data Manager2 locations (listed on the posting)Sep 23, 2026Oct 7, 2026Senior
Executive Director, R&D Strategy & Operations2 locations (listed on the posting)Sep 23, 2026Oct 7, 2026Executive
Associate Director, FILSPARI HCP Marketing2 locations (listed on the posting)Sep 23, 2026Oct 7, 2026Senior
Flex Medical Science Liaison - West9 locations, including Remote, CaliforniaSep 23, 2026Oct 7, 2026Mid
Flex Medical Science Liaison - East8 locations, including Remote, New YorkSep 23, 2026Oct 7, 2026Mid
Senior Specialist, Regulatory AffairsRapperswil-Jona (SG), SwitzerlandSep 23, 2026Oct 7, 2026Senior
Associate Director, Technical Operations (Small Molecule CMC)2 locations (listed on the posting)Sep 23, 2026Oct 7, 2026Senior
Chief Scientific Officer2 locations (listed on the posting)Sep 23, 2026Oct 7, 2026Executive
Associate Director, Legal ContractsSan DiegoSep 23, 2026Oct 7, 2026Senior
Vice President, Financial Planning & Analysis2 locations (listed on the posting)Sep 23, 2026Oct 7, 2026Executive
Associate Director, Technical Operations - Drug Product2 locations (listed on the posting)Sep 23, 2026Oct 7, 2026Senior
Senior Total Rewards AnalystSan DiegoSep 23, 2026Oct 7, 2026Senior
Manager, Regulatory Affairs Strategy2 locations (listed on the posting)Sep 23, 2026Oct 7, 2026Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $143.8M · Debt: $475.0M. Last 2 years.

Clinical trials (lead sponsor) 14

RecordTitlePhaseStatusStartPrimary completion
NCT06247085Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care TreatmentPhase 3RecruitingDec 28, 20232027-08 (estimated)
NCT02998710Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)Not listedCompleted2017-01Jul 31, 2026 (actual)
NCT03406611Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)Phase 1/Phase 2RecruitingJan 22, 20192027-07 (estimated)
NCT07219121Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental GlomerulosclerosisPhase 4Active, not recruitingOct 7, 20252027-03 (estimated)
NCT06431893A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)Phase 3Enrolling by invitationApr 30, 20242030-08 (estimated)
NCT05003986Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesPhase 2RecruitingAug 12, 2021Mar 12, 2027 (estimated)
NCT03762850A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyPhase 3Active, not recruitingDec 11, 2018Aug 7, 2023 (actual)
NCT03493685Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)Phase 3CompletedApr 17, 2018Mar 20, 2023 (actual)
NCT05856760A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgANPhase 2CompletedMay 19, 2023Oct 14, 2024 (actual)
NCT01613118Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisPhase 2Completed2014-032016-06 (actual)
NCT02638220Cerebrotendinous Xanthomatosis (CTX) Prevalence StudyNot listedCompleted2015-09Feb 19, 2021 (actual)
NCT05200871Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)Not listedCompletedFeb 5, 2022Oct 31, 2023 (actual)
NCT05562362Study to Evaluate the Pharmacokinetics of Oral Sparsentan SuspensionPhase 1CompletedJun 18, 2020Nov 12, 2020 (actual)
NCT03041116Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN ParticipantsPhase 3TerminatedJul 17, 2017Dec 30, 2019 (actual)

FDA records (last 2 years)

Connect

See your connections at Travere Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback